title: Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component.
abstract: OBJECTIVE
  To evaluate clinical characteristics including the response to targeted therapy, the benefits of cytoreductive nephrectomy, or the prognostic factors in advanced renal cell carcinoma (RCC) with extensive sarcomatoid component (ESC), a rare but fatal disease.
  
  
  METHODS
  Data from 37 consecutive patients with metastatic or recurrent RCC with ESC (≥25 % on resected kidney or exclusive sarcomatoid histology on needle biopsy) were analyzed.
  
  
  RESULTS
  Of the 37 patients, 27 patients (73 %) had synchronous metastatic disease. The median percentage of sarcomatoid component (PSC) was 50 % (range 25-93 %). Twenty (74 %) of the 27 synchronous metastatic patients underwent cytoreductive nephrectomy. Of the nine patients undergoing cytokine therapy, none showed objective responses. Two (15 %) of the 13 patients undergoing targeted agent therapy had partial responses, and five patients (38 %) achieved stable disease. The median overall survival for all patients was 5.9 months [95 % confidence interval (CI) 1.0-10.9]. In multivariate analysis, age (>58 years), ECOG performance status (>1), PSC (>50 %), and time from first diagnosis to advanced disease (<6 months) remained independent prognostic factors. Neither the type of systemic therapy nor cytoreductive nephrectomy had an effect on survival.
  
  
  CONCLUSIONS
  Patients with RCC with ESC have a dismal clinical course, and the majority of patients have rapid disease progression, especially in response to immunotherapy. Four clinical factors can be used to model survival outcomes for advanced RCC with ESC and may be helpful in selecting patients for aggressive treatment.
authors: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-gu, Seoul 138-736, Korea. ingni79@hanmail.net
authors: Inkeun
authors: I
authors: Park
authors: Yong Mee
authors: YM
authors: Cho
authors: Jae-Lyun
authors: JL
authors: Lee
authors: Jin-Hee
authors: JH
authors: Ahn
authors: Dae-Ho
authors: DH
authors: Lee
authors: Cheryn
authors: C
authors: Song
authors: Jun-Hyuk
authors: JH
authors: Hong
authors: Choung-Soo
authors: CS
authors: Kim
authors: Hanjong
authors: H
authors: Ahn
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009378:Neoplasms, Multiple Primary / Q000473:pathology; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome
references: Oncology. 2011;80(3-4):214-8
references: 21720184
references: Eur Urol. 1995;27(2):138-41
references: 7744156
references: J Urol. 2010 Nov;184(5):1877-81
references: 20850148
references: J Clin Oncol. 2011 Mar 10;29(8):e203-5
references: 21172884
references: Am J Clin Oncol. 2011 Oct;34(5):454-9
references: 21127411
references: Cancer. 1987 Sep 15;60(6):1313-8
references: 2441841
references: J Clin Oncol. 2009 Jan 10;27(2):235-41
references: 19064974
references: Eur Urol. 2006 May;49(5):798-805
references: 16442207
references: J Urol. 2002 Jan;167(1):65-70
references: 11743277
references: J Clin Oncol. 2004 Apr 1;22(7):1188-94
references: 14981107
references: J Urol. 2007 Apr;177(4):1258-63
references: 17382701
references: Eur J Med Res. 2010;15:287-91
references: 20696639
references: J Surg Oncol. 2007 Mar 15;95(4):317-23
references: 17066434
references: J Urol. 2002 Sep;168(3):959-61
references: 12187199
references: Med Oncol. 1998 Apr;15(1):44-9
references: 9643530
references: J Clin Oncol. 2009 Dec 1;27(34):5794-9
references: 19826129
references: J Urol. 2009 Nov;182(5):2164-71
references: 19758641
references: Am J Surg Pathol. 2001 Mar;25(3):275-84
references: 11224597
references: Ann Oncol. 2001 Feb;12(2):271-4
references: 11300337
references: Cancer. 2010 Feb 1;116(3):616-24
references: 19998348
references: J Clin Oncol. 1999 Feb;17(2):523-8
references: 10080595
references: J Urol. 2011 Jan;185(1):60-6
references: 21074201
references: Lancet. 2001 Sep 22;358(9286):966-70
references: 11583750
references: Cancer. 1987 Feb 1;59(3):516-26
references: 3791160
references: J Cancer Res Clin Oncol. 2012 Apr;138(4):687-93
references: 22237457
references: Cancer. 2003 Dec 15;98(12):2566-75
references: 14669275
references: J Clin Oncol. 2004 Feb 1;22(3):454-63
references: 14752067
references: Med Oncol. 2012 Jun;29(2):761-7
references: 21298497
references: Cancer. 2004 Oct 1;101(7):1545-51
references: 15378501
references: Cancer. 2015 Oct 1;121(19):3435-43
references: 26058385
references: Oncologist. 2012;17(1):46-54
references: 22234634
references: N Engl J Med. 2001 Dec 6;345(23):1655-9
references: 11759643
references: Am J Surg Pathol. 2004 Apr;28(4):435-41
references: 15087662